FY2026-2035 · CBO February 2026 baseline

Comprehensive Drug Reform

Expanded negotiation + insulin cap + manufacturer discounts. **No official score**: nothing published scores a *combined* package of these three, and the nearest published figures are components an order of magnitude smaller (CBO put the IRA's own negotiation at $98.5B over FY2022-2031). The model's own estimate is the only number shown, and it is a 🟡 reconstruction of a channel nobody has scored. **Illustrative**: shown for the shape of the policy rather than as an estimate of it.

Ten-year deficit effect, conventional-$158.9Breduces the deficit
With macroeconomic feedback and debt service-$178.6BFRB/US-Lite (Federal Reserve calibrated)
Checked against

No published score for this exact policy is on file.

No out-of-sample band: no pre-registered row scores a drug-pricing reform. The 44 pre-registered Tier 1 rows are the only tier that measures this model's accuracy, and none of them scores a policy of this kind.

Year by year

billions, conventional
Fiscal yearRevenueDeficit, conventionalMacro feedbackDebt serviceDeficit, dynamic
2026$0.0B-$15.9B-$2.8B-$0.6B-$13.7B
2027$0.0B-$15.9B-$3.2B-$1.3B-$14.0B
2028$0.0B-$15.9B-$2.7B-$1.9B-$15.1B
2029$0.0B-$15.9B-$2.1B-$2.5B-$16.3B
2030$0.0B-$15.9B-$1.5B-$3.2B-$17.5B
2031$0.0B-$15.9B-$1.1B-$3.8B-$18.6B
2032$0.0B-$15.9B-$0.7B-$4.4B-$19.6B
2033$0.0B-$15.9B-$0.5B-$5.1B-$20.5B
2034$0.0B-$15.9B-$0.3B-$5.7B-$21.3B
2035$0.0B-$15.9B-$0.2B-$6.4B-$22.0B

Download CSV

Who pays

first year, by income group

This is a spending or sector policy, so there is no tax table by income group.

Economic effects

difference from the CBO baseline
GDP, summed over the window-0.22percent-years
Jobs at the largest effect-29K
Deficit effect of the GDP change+$15.2Bless tax collected
Deficit effect of interest on the debt-$34.9Bless debt, less interest
Fiscal yearGDP levelJobsUnemployment10-year rateGDP change, deficitInterest, deficit
2026-0.040%-25K+0.02 pt-0.00 pt+$2.8B-$0.6B
2027-0.045%-29K+0.02 pt-0.00 pt+$3.2B-$1.3B
2028-0.039%-25K+0.02 pt-0.01 pt+$2.7B-$1.9B
2029-0.030%-19K+0.02 pt-0.01 pt+$2.1B-$2.5B
2030-0.022%-14K+0.01 pt-0.01 pt+$1.5B-$3.2B
2031-0.015%-10K+0.01 pt-0.01 pt+$1.1B-$3.8B
2032-0.011%-7K+0.01 pt-0.01 pt+$0.7B-$4.4B
2033-0.007%-5K+0.00 pt-0.01 pt+$0.5B-$5.1B
2034-0.005%-3K+0.00 pt-0.02 pt+$0.3B-$5.7B
2035-0.003%-2K+0.00 pt-0.02 pt+$0.2B-$6.4B

FRB/US-Lite (Federal Reserve calibrated). Demand effects fade over five to seven years as monetary policy responds; there is no supply-side channel. The dynamic score is the conventional score, plus the deficit effects of the GDP change and of interest on the debt: -$158.9B + $15.2B - $34.9B = -$178.6B.

Other scoring models

exploratory
ModelTen-year deficit effectMethod
CBO-Style-$158.9BStatic + ETI behavioral response + optional FRB/US dynamic feedback
TPC-Microsim PilotCannot score thisComprehensive Drug Pricing Reform (DrugPricingPolicy) does not map onto current microsim pilot reforms (income-tax rates, CTC, EITC, SALT, std deduction, AMT exemption).

No pilot model returned distributional output; the comparison is aggregate-only.

CBO-Style is the model behind the headline above. The TPC-style microsimulation is a pilot: where the two disagree, the gap tells you how much the answer depends on method. It is not an official range.

Limitations

Cite asWilse-Samson, Laurence. “Comprehensive Drug Reform.” Fiscal Policy Calculator, CBO February 2026 baseline, FY2026-2035. https://fiscal.lwilsesamson.com/explore/drug-reform-comprehensive